6 Best Price Comparison for November 2025

6 Best Price Comparison for November 2025

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Market Overview & Selection Criteria

The 2025 equity landscape is defined by volatility, sector rotation, and a renewed focus on intrinsic value. Our methodology prioritizes stocks with strong free cash flow, robust margins, and favorable ValueSense quality ratings. We screen for companies trading below their estimated intrinsic value, with an emphasis on diversified sector exposure and risk-adjusted growth potential. Each stock is evaluated using ValueSense’s proprietary metrics, including quality rating, financial health, and recent performance trends.

Ziff Davis, Inc. (ZD)

MetricValue
Market Cap$1,428.6M
Quality Rating6.0
Intrinsic Value$143.1
1Y Return-26.7%
Revenue$1,447.2M
Free Cash Flow$233.1M
Revenue Growth5.9%
FCF margin16.1%
Gross margin82.4%
ROIC3.0%
Total Debt to Equity47.0%

Investment Thesis

Ziff Davis, Inc. stands out as a digital media and internet company with a market cap of $1.43B, offering a blend of high gross margins 82.4% and consistent free cash flow $233.1M. Despite a challenging year (-26.7% 1Y return), the company’s intrinsic value is estimated at $143.1, suggesting significant upside from current levels. Its quality rating of 6.0 reflects stable operations and a strong content-driven business model.

Key Catalysts

  • High gross margin supports profitability even in volatile markets
  • Free cash flow margin of 16.1% enables reinvestment and debt management
  • Revenue growth of 5.9% signals resilience in a competitive sector

Risk Factors

  • Elevated total debt to equity 47.0% could pressure future flexibility
  • Modest ROIC 3.0% may limit long-term compounding
  • Recent negative price momentum (-26.7% 1Y return) could deter short-term sentiment

GoodRx Holdings, Inc. (GDRX)

MetricValue
Market Cap$1,201.8M
Quality Rating7.0
Intrinsic Value$15.5
1Y Return-44.9%
Revenue$799.9M
Free Cash Flow$157.6M
Revenue Growth3.2%
FCF margin19.7%
Gross margin91.2%
ROIC9.6%
Total Debt to Equity85.1%

Investment Thesis

GoodRx Holdings, Inc. is a healthcare technology platform with a $1.20B market cap, specializing in prescription price transparency. The company’s quality rating of 7.0 and gross margin of 91.2% highlight operational efficiency. While the 1Y return is -44.9%, the intrinsic value of $15.5 per share points to a potential value opportunity for patient investors.

Key Catalysts

  • Leading position in digital healthcare cost savings
  • Strong free cash flow margin 19.7% and $157.6M FCF
  • High gross margin 91.2% supports scalable growth

Risk Factors

  • High total debt to equity 85.1% increases financial risk
  • Slower revenue growth 3.2% may limit near-term upside
  • Recent underperformance (-44.9% 1Y return) reflects sector headwinds

QuinStreet, Inc. (QNST)

MetricValue
Market Cap$844.0M
Quality Rating6.4
Intrinsic Value$9.5
1Y Return-29.6%
Revenue$1,093.7M
Free Cash Flow$80.5M
Revenue Growth78.3%
FCF margin7.4%
Gross margin10.1%
ROIC2.0%
Total Debt to Equity3.0%

Investment Thesis

QuinStreet, Inc., with a market cap of $844M, operates in digital marketing and performance-based advertising. The company’s revenue growth of 78.3% is a standout, though its gross margin is lower at 10.1%. A quality rating of 6.4 and intrinsic value of $9.5 suggest a balanced risk/reward profile, especially for investors seeking exposure to digital advertising trends.

Key Catalysts

  • Exceptional revenue growth 78.3% driven by digital transformation
  • Low total debt to equity 3.0% enhances financial stability
  • Free cash flow of $80.5M supports ongoing innovation

Risk Factors

  • Low gross margin 10.1% may limit profitability
  • Modest ROIC 2.0% and FCF margin 7.4%
  • 1Y return of -29.6% signals recent market skepticism

EverQuote, Inc. (EVER)

MetricValue
Market Cap$782.5M
Quality Rating7.9
Intrinsic Value$88.2
1Y Return19.8%
Revenue$615.2M
Free Cash Flow$89.9M
Revenue Growth92.9%
FCF margin14.6%
Gross margin96.6%
ROIC126.6%
Total Debt to Equity3.0%

Investment Thesis

EverQuote, Inc. is a digital insurance marketplace with a $782.5M market cap and a strong 1Y return of 19.8%. The company’s quality rating of 7.9 is the highest in this collection, and its revenue growth 92.9% and gross margin 96.6% are exceptional. With an intrinsic value of $88.2, EverQuote is positioned as a high-growth, high-quality play in fintech.

Key Catalysts

  • Leading revenue growth 92.9% and gross margin 96.6%
  • Outstanding ROIC 126.6% reflects capital efficiency
  • Low total debt to equity 3.0% supports balance sheet strength

Risk Factors

  • High growth may attract competition and regulatory scrutiny
  • FCF margin 14.6% is solid but could fluctuate with market cycles
  • Digital insurance sector can be sensitive to macroeconomic shifts

MoneyHero Limited Class A Ordinary Shares (MNY)

MetricValue
Market Cap$55.8M
Quality Rating4.3
Intrinsic Value$11.3
1Y Return11.0%
Revenue$69.0M
Free Cash Flow$0.0
Revenue Growth(22.1%)
FCF margin0.0%
Gross margin49.0%
ROIC(572.5%)
Total Debt to Equity2.1%

Investment Thesis

MoneyHero Limited is a fintech company with a $55.8M market cap, focusing on personal finance solutions in Asia. Despite a 1Y return of 11.0%, the company faces challenges, including negative revenue growth -22.1% and a low quality rating 4.3. The intrinsic value of $11.3 suggests some upside, but operational risks are elevated.

Key Catalysts

  • Exposure to fast-growing Asian fintech markets
  • Gross margin of 49.0% provides a base for future profitability
  • Recent positive price momentum (11.0% 1Y return)

Risk Factors

  • Negative revenue growth and zero free cash flow
  • Extremely negative ROIC -572.5% and low FCF margin
  • Small market cap increases volatility and liquidity risk

Advent Technologies Holdings, Inc. (ADN)

MetricValue
Market Cap$2,447.9K
Quality Rating5.3
Intrinsic Value$342.1
1Y Return-47.8%
Revenue$115.0K
Free Cash Flow$4,965.0K
Revenue Growth(98.4%)
FCF margin4,317.4%
Gross margin(1,319.1%)
ROIC254.3%
Total Debt to Equity(5.7%)

Investment Thesis

Advent Technologies Holdings is a micro-cap company ($2.45M market cap) in the advanced materials and fuel cell sector. The company’s intrinsic value is estimated at $342.1, but recent performance (-47.8% 1Y return) and negative gross margin -1,319.1% highlight significant operational challenges. The quality rating of 5.3 and a unique FCF margin 4,317.4% reflect a high-risk, high-reward profile.

Key Catalysts

  • Exposure to green energy and fuel cell innovation
  • Positive ROIC 254.3% despite negative gross margin
  • Potential for outsized returns if operational turnaround succeeds

Risk Factors

  • Extremely small market cap and high volatility
  • Negative revenue growth -98.4% and gross margin
  • Unconventional capital structure (negative debt to equity)

Portfolio Diversification Insights

This watchlist spans digital media, healthcare technology, fintech, digital marketing, insurance, and advanced materials, offering exposure to both growth and value segments. The inclusion of micro-cap (ADN), small-cap (MNY, EVER, QNST), and mid-cap (ZD, GDRX) stocks helps balance risk and opportunity. Sector allocation is weighted toward technology-enabled business models, with select exposure to healthcare and green energy for diversification.

Market Timing & Entry Strategies

Given the volatility in small- and mid-cap equities, staggered entry or dollar-cost averaging may help manage risk. Monitoring sector rotation and macroeconomic signals can inform optimal entry points. Investors may consider waiting for technical confirmation or improved sentiment, especially for stocks with recent negative momentum. For high-growth names, scaling in over time can reduce timing risk.


Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best overall value plays for 2025)

📌 50 Undervalued Dividend Stocks (For income-focused investors)

📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!



FAQ Section

Q1: How were these stocks selected?
Stocks were chosen based on ValueSense’s proprietary screening, focusing on intrinsic value, quality rating, financial health, and sector diversification, using only verified data from ValueSense platform screenshots.

Q2: What's the best stock from this list?
There is no single “best” stock, as each offers unique strengths; however, EverQuote (EVER) currently holds the highest quality rating 7.9 and strongest revenue growth, while Ziff Davis (ZD) and GoodRx (GDRX) offer compelling value based on intrinsic value estimates.

Q3: Should I buy all these stocks or diversify?
Diversification across sectors and market caps can help manage risk; this collection is designed to provide exposure to multiple themes, but allocation should be tailored to individual risk tolerance and investment objectives.

Q4: What are the biggest risks with these picks?
Key risks include sector volatility, negative recent returns for several stocks, high debt levels (notably GDRX), and operational challenges for micro-cap and turnaround plays like ADN and MNY.

Q5: When is the best time to invest in these stocks?
Market timing is inherently uncertain; strategies such as dollar-cost averaging and monitoring for technical or fundamental catalysts can help manage entry risk, especially in volatile or underperforming names.


For more in-depth analysis and real-time updates, visit ValueSense and explore our full suite of research tools.